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Abstract 
Introduction and aims: Development of Acute Kidney Injury (AKI) following the use of 
antibiotics such as sulphonamides, trimethoprim and aminoglycosides is a frequently 
described phenomenon. More recently an association between fluoroquinolone use and AKI 
has been suggested. The aim of this study was to evaluate the risk of AKI as an unintended 
consequence of commonly prescribed antibiotics in a large community cohort using a 
method that fully adjusts for underlying patient characteristics, including potential 
unmeasured confounders.  
Methods: A self-controlled case study was conducted and included all individuals aged 18 
and over in the Tayside region of Scotland who had a serum creatinine measured between 
1st January 2004 and 31st December 2012. AKI episodes were defined using the Kidney 
Disease Improving Global Outcomes (KDIGO) definition. Data on oral community prescribed 
antibiotics (penicillins, cephalosporins, fluoroquinolones, sulphonamides and trimethoprim, 
macrolides and nitrofurantoin) were collected for all individuals. Incidence rate ratios (IRR) 
for AKI associated with antibiotic exposure versus time periods without antibiotic exposure 
were calculated.  
Results:  Combined use of sulphonamides, trimethoprim and nitrofurantoin rose by 47% and 
incidence of community acquired AKI rose by 16% between 2008 and 2012. During the 
study period 12,777 individuals developed 14,900 episodes of AKI in the community, of 
which 68% was AKI stage 1, 16% stage 2 and 16% stage 3. The incidence rate ratio (IRR) of 
AKI during any antibiotic use was 1.16 95% CI (1.10 – 1.23), this was highest during 
sulphonamides or trimethoprim use; IRR 3.07 95% CI (2.81 – 3.35). Fluoroquinolone and 
nitrofurantoin use was not associated with a significantly increased rate of AKI; IRR 1.13 
95% CI (0.94 – 1.35) and 1.16 95%CI (0.91 – 1.50) respectively.  
Conclusion: Incidence of AKI rose by 16% between 2008 and 2012. In the same period use 
of sulphonamides, trimethoprim and nitrofurantoin increased by 47%. A significant increased 
risk of AKI was seen with the use of sulphonamides and trimethoprim, but not with 
fluoroquinolones or nitrofurantoin. 
 
Keywords: AKI, community prescribed antibiotics, self -controlled case series  
Introduction 
Acute kidney injury (AKI) is associated with both short and long-term morbidity and 
mortality(1-4). There is increasing evidence suggesting that even a small transient rise in 
serum creatinine is associated with increased risk of cardiovascular disease and future 
development of chronic kidney disease(4-6). The National Institute for Health and Care 
Excellence highlighted in 2013 that AKI is increasingly common in primary care in people 
without any acute illness and awareness of the condition needs to be raised among primary 
care health professionals(7, 8).  
There is emerging evidence that antibiotics commonly prescribed in the community are 
associated with adverse effects on renal function. In particular the development of AKI 
following the use of sulphonamides, nitrofurantoin and trimethoprim has been well 
described(9-11). A recent large British cohort study showed an increase of 72% and 48% in 
the odds of AKI following treatment with trimethoprim and ciprofloxacin respectively for UTI 
in older patients in the community(12).  A large Canadian case control study also reported a 
two-fold increase of hospital acquired AKI during fluoroquinolone administration (17). 
Potential causal effects of fluoroquinolones on collagen and connective tissue damage have 
been suggested following reports of tendon ruptures(13) and retinal attachment(14).  Badal 
et al(15) described fluoroquinolone dependent iron chelation pathways causing inhibition of 
collagen maturation and subsequent renal toxicity. Despite plausible biological mechanisms, 
a potential criticism of associations from observational studies is that people who receive 
antibiotics are at risk of AKI for other reasons, including comorbidity, frailty and concurrent 
medications, which are difficult to fully adjust for.  
Over four million individual antibiotic prescriptions were dispensed in the community across 
Scotland during 2009(16). Ten percent of these were sulphonamides and trimethoprim, 2% 
nitrofurantoin and 5% fluoroquinolones(17). The aim of this study was to evaluate the risk of 
AKI of common community prescribed antibiotics on renal function in a large community 
cohort of adults, using a self-controlled case series design to avoid inter-person 
confounding.  
Methods 
Data sources 
The routinely recorded anonymised datasets were provided by the Health Informatics Centre 
(HIC) at the University of Dundee (18), which enables anonymised linkage of health records 
from the population of Tayside, Scotland (population approximately 400,000), using the 
unique identifying Community Health Index (CHI) number, which is associated with all 
National Health Service (NHS) healthcare use. Data from the following datasets were linked: 
Scottish Morbidity Record of hospital admissions (SMR01); laboratory results, medicines 
dispensed by community pharmacies, the Scottish Care Initiative-Diabetes Collaboration and 
Scottish Renal Registry.  
SMR01 provides information on age, sex, postcode, admission and discharge dates. Serum 
creatinine measurements over the complete study period were obtained from the laboratory 
system. Dispensed quantity of antibiotics was available for all antibiotic prescriptions. 
Missing drug name, strength or formulation values were imputed for prescriptions using 
those that had complete information available. The imputation was carried out in succession 
merging on maximum possible variables and replacing the missing values with the most 
common direction of use.  Data were linked with the Scottish Care Initiative-Diabetes 
Collaboration and Scottish Renal Registry, identifying individuals with diabetes mellitus and 
end stage renal disease.  
Study population 
We identified all adult individuals, residing in the Tayside region of Scotland who had 
received at least one community prescribed antibiotic and had a minimum of two serum 
creatinine measurements between 1st January 2004 and 31st December 2012. Observation 
periods for each individual were divided into those with and without exposure to an antibiotic. 
Individual antibiotic prescriptions with duration longer than 28 days were classed as ‘chronic 
antibiotic use’ and excluded from the analysis. Additionally, periods of antibiotic use other 
than via the oral route, antibiotic use during an in-patient stay or within 30 days of hospital 
discharge were excluded.  
Definitions 
Baseline serum creatinine used for the detection and classification of AKI cases was 
calculated as a median of serum creatinine measurements taken 8 to 365 days prior to the 
AKI detection date. If no such measurement was available, the nadir creatinine 
measurement taken between 0 to 7 days prior to the AKI detection date was used. An AKI 
episode was defined by the first serum creatinine measurement ≥1.5 times the baseline 
serum creatinine. KDIGO AKI staging criteria were used to define AKI stage(19) 
A unique observation period was defined for each individual starting on the day of their first 
eligible antibiotic prescription or first eligible creatinine measurement during the study period 
(whichever was earlier) and ended on the last day of the final eligible antibiotic course, the 
last eligible creatinine measurement or the end of the study period (whichever was earlier). 
Risk periods associated with antibiotic use were defined as the start of the prescription until 
14 days after the end of the prescription. Consecutive AKI episode(s) within the seven days 
following a previous AKI episode was considered as one AKI event.  Patients who became 
dialysis dependent during the study period were censored from the day of starting chronic 
dialysis.   
Study design  
The self-controlled case series (SCCS) design relies on comparisons within people in a 
population of individuals who have both the outcome (AKI) and intermittent exposure 
(antibiotic use) of interest. The SCCS method is particularly useful when examining acute 
and recurrent outcomes after transient exposures for which exact timings are available. A 
typical timeline charting AKI episodes (events) in relation to exposure to antibiotics (risk 
periods) is illustrated in figure 1. The major advantage of the SCCS design is that it controls 
for within-person confounders that do not vary significantly over time such as demographics, 
comorbidities and concurrent chronic medication use.  
Incidence rate ratios were calculated comparing the rate of events during risk periods with 
the rate during all other observed time periods. Individuals were stratified by age category 
(18-40, 41-60, 61-80, 81 or older) and outcomes were adjusted for this single time-varying 
covariate. All analyses were conducted using SAS 9.4 and STATA v14.  
Ethics 
Anonymised record linkage within the safe haven was conducted in accordance with HIC 
Standard Operating Procedures (SOP). These are approved by The East of Scotland 
Research Ethics Service and the NHS Tayside Caldicott Guardian with agreement that 
studies adhering to the SOP do not require individual ethical review. 
Results 
Characteristics of community antibiotic prescribing 
During the 9 year study period a total of 1,765,764 community antibiotic prescriptions were 
dispensed to 249,117 individuals in NHS Tayside. In line with national prescribing 
policies(17) the majority of individuals received penicillin (57%), 14% received sulphonamide 
or trimethoprim, 6% fluoroquinolones and 4% nitrofurantoin. The majority of fluoroquinolone 
prescribing was ciprofloxacin (91.9%). Levofloxacin was prescribed in 3.9% followed by 
ofloxacin (2.8%) with the remainder comprising of moxifloxacin and norfloxacin. Dosing 
regimens for all antibiotic exposures and for antibiotic exposures with AKI are shown in 
Table 1. 
A 14% reduction of community prescribed antibiotic courses from 535 to 457 per 1000 
population was evident between 2008 and 2012. In accordance with prescribing guidelines, 
reductions in fluoroquinolone, cephalosporin and macrolide prescriptions per 1000 
population (-75%, -70% and -35% respectively) and increases in trimethoprim and 
sulphonamide (+15%) and nitrofurantoin (+163%) prescriptions per 1000 population were 
observed between 2008 and 2012 (Figure 2). 
 
Characteristics of individuals analysed in self -controlled case series 
Of the 249,117 individuals that received one or more antibiotic prescription between 1st 
January 2004 and 31st December 2012, 12,777 individuals with one or more episodes of AKI 
were included in our analysis. The median number of creatinine measurements over 8-365 
days used to calculate the baseline for AKI was 8 (IQR: 2 -20). A flow diagram of inclusion is 
presented in Figure 3. Included individuals contributed to 94,859 exposed risk periods and 
85,282 unexposed (control) periods during the whole study period. 
The mean age of individuals at onset of first AKI was 69 (SD±18) years and 57% (7230) 
were female. Median creatinine was 96 μmol/L (IQR 82-117), 17% (2148) were diabetic and 
70% (8952) received cardiovascular medication at the start of the observation period (Table 
2). 
Associations between antibiotic use and AKI 
During the study period 12,777 individuals developed 14,900 episodes of AKI. Twenty one 
percent of individuals had two or more episodes of AKI. Sixty eight percent of episodes, 
were stage 1 AKI, 16% were stage 2 and 16% stage 3. Of the 2310 AKI 3 episodes, 73% 
were admitted to hospital with a median of 0 days to admission (IQR: 0 -16). Incidence rate 
of AKI was 17.6 per 100 person years in 2008 and rose to 20.5 per 100 person years in 
2012. Mean number of daily doses and duration of antibiotic exposure by AKI stage is shown 
in Table 3.The incidence rate ratio (IRR) of AKI during antibiotic risk periods for any antibiotic 
as a composite endpoint compared to periods without antibiotics was 1.16 (95%CI 1.10 – 
1.23). For individual antibiotic risk periods, the IRR of AKI was highest during sulphonamides 
or trimethoprim use; IRR 3.07 (95% CI 2.81 – 3.35). Fluoroquinolones were associated with 
increased rates of AKI; IRR 1.17 (95%CI 0.98 – 1.39) () but did not reach statistical 
significance at the 5% level (Figure 4).  
 
Discussion 
Using a self-controlled case series design, we observed a 1.16 times increased incidence 
rate ratio of AKI in individuals receiving community prescribed antibiotics compared to those 
not receiving antibiotics. This increased to a 3 fold increased risk of AKI in individuals 
receiving trimethoprim or sulphonamides. Duration of antibiotic exposure or number of daily 
doses was not associated with increased severity of AKI. Treatment with penicillin showed a 
reduction in IRR of 0.8 (95% CI 0.74- 0.86). According to local community antibiotic 
prescribing guidelines, penicillin is recommended as first choice antibiotic for non-severe 
chest infections, skin and ENT infections. It is likely that the low IRR of AKI represents a 
selected patients group in the absence of a severe systemic illness, rather than a direct 
effect of penicillin on renal function. In contrast to previous cohort studies (12, 20, 21), there 
was no increase in risk associated with oral fluoroquinolone use or antibiotics from other 
individual classes although there was an association of a similar order with IRR of 1.17. 
Fluoroquinolone induced AKI has been described in a retrospective nested case-control 
study from Canada (22) which reported a 2-fold increase in relative risk of hospital acquired 
AKI during concomitant use of fluoroquinolones. These results should be interpreted with 
caution due to confounding by indication and selection bias. Confounding by indication is 
reduced in a case-crossover design. Groups were not comparable with regards to indication 
for fluoroquinolone use with a greater proportion of cases suffering from genitourinary tract 
infections compared to the controls. Baseline characteristics also differed with significantly 
higher rates of hypertension, diabetes mellitus, congestive heart failure and a higher 
proportion of patients taking inhibitors of the renin-angiontensin system and loop diuretics in 
those receiving fluoroquinolones. Case reports (23-25) highlighted crystalluria induced AKI 
following fluoroquinolone use but this is thought to be exceedingly rare as it depends on a 
urine pH of greater than 6.8 to develop.  
Scottish antibiotic prescribing guidance(26) published in 2010 aimed to reduce the incidence 
of Clostridium difficile infections and overall antibiotic use. This guidance promotes the use 
of sulphonamides, trimethoprim and nitrofurantoin amongst others for first line empirical 
treatment of urinary tract infections in a primary care setting. Since then, a decrease in the 
total community antibiotic prescriptions per 1000 population has been observed. In particular 
broad-spectrum antibiotics such as fluoroquinolones, cephalosporins and macrolides were 
prescribed on a lesser scale. This was directly associated with a 15% increase in community 
prescriptions of nitrofurantoin per 1000 population and a 1.6 time increase in sulphonamides 
and trimethoprim use per 1000 population between 2008 and 2012 in NHS Tayside. A 
concurrent 16% increase in incidence of AKI was observed from 2008 to 2012. This study 
confirmed the previously described associations between sulphonamides and trimethoprim 
use and AKI using data from a complete population of one Scottish Health Board over a long 
period of observation. Whether the increase in AKI in the community is associated with the 
change in antibiotic policy, as an unintended consequence, is worthy of further investigation 
within Tayside and across Scotland.  
Our study has several strengths. Analyses were performed using routinely collected 
prescribing and biochemistry data from the whole NHS Tayside population (population 
approximately 400,000) over a 9 year period, thus comprising a heterogeneous and 
representative cohort with a substantial follow up period. Within-person confounding was 
minimised due to the use of a self-controlled case series design when comparing the risk of 
AKI during periods of antibiotic exposure to periods of no antibiotic use within the same 
patient(27).  
Limitations of this study are inherently related to the retrospective design of the study and 
the lack of detailed information about 1) baseline co-morbidities of our cohort and 2) 
indication for antibiotic use. Firstly, individuals with cardiovascular disease or diabetes, 
accounting for 70% and 17% of our study population respectively, may have their kidney 
function checked more frequently in a community setting. This may have contributed to 
selecting a higher risk subgroup from the Tayside population into our observed cohort. 
Confounding by the effect of comorbidity on AKI incidence, however, is minimised by the 
self-controlled case series design. Secondly, an increased incidence of AKI following 
sulphonamides and trimethoprim use may be related to intercurrent illnesses for which it was 
prescribed and it is important to note that the rise in creatinine caused by this class of 
antibiotics  may be due to inhibition of tubular secretion rather than a “true AKI”(9, 28). 
Unfortunately there are no data available on the indication for antibiotic prescriptions in our 
cohort however current antibiotic guidance in our health board is shown in Supplementary 
Information. According to this guidance the majority of sulphonamides and trimethoprim, 
cephalosporins and nitrofurantoin prescribing were likely to be for urinary tract infections. 
The majority of macrolide prescribing was likely to be for chest infections as was most of the 
penicillin prescribing.  
Using a study design which adjusted for confounding to a greater extent than other 
observational designs, our findings confirm the previously well-described increased risk of 
AKI with the use of community prescribed antibiotics, in particular sulphonamides and 
trimethoprim. However, we did not find any clear evidence in this large, heterogeneous 
cohort to suggest that fluoroquinolones are associated with increased of AKI in the 
community.  
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Figure 1: Self-Controlled Case Series design 
  
 Figure 2: Antibiotic prescriptions in NHS Tayside from 2004 – 20012 per 1000 population for 
each of the 6 main antibiotic classes studied 
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Figure 3: Flow diagram for patient inclusions 
 
  
Table 1: Antibiotic dosing regimen in all antibiotic exposures and for exposures with AKI by 
antibiotic class 
 
 
 
 
 
 
 
 
 
 All antibiotic exposures                
mean (SD) 
Antibiotic exposure with AKI 
mean (SD) 
Antibiotic class Number of 
doses per day 
Duration of 
prescription  
(days) 
Number of 
doses per day 
Duration of 
prescription 
(days) 
Cephalosporins 3.68 (2.44) 7.36 (3.47) 4.62 (4.19) 6.76 (1.26) 
Fluoroquinolones 2.12 (1.69) 7.94 (4.65) 2.23 (2.12) 9.48 (6.79) 
Macrolides 3.46 (3.27) 7.56 (3.48) 3.7 (3.54) 7.55 (3.37) 
Nitrofurantoins 3.33 (3.03) 7.74 (5.66) 3.47 (4.57) 8.57 (6.68) 
Penicillins 4.01 (3.83) 7.11 (2.13) 4.71 (5.06) 7.31(2.56) 
Sulphonamides & 
Trimethoprims 
2.43 (4.15) 6.78 (5.42) 2.16 (3.23) 8.87 (7.4) 
 N = 12777 Patient characteristics 
 
Start of 
observation period 
End of 
observation period 
Female; N (%) 7230 (57) 
Age; years (mean ± SD) 68.8 ± 17.6 
Receiving cardiovascular 
medication; N (%)* 
8952 (70.1) 11058 (86.5) 
Diabetes Mellitus; N (%) 2148 (16.8) 3427 (26.8) 
Creatinine; μmol/L; 
(median (IQR) 
96 (82-117) 112 (76-174) 
 
 
 
 
Table 2: Patient characteristics at start of observation period (N=12777) 
* Receiving cardiovascular medication is defined as any drug prescription mentioned in chapter 2 of 
British National Formulary, including management of arrhythmias, bleeding disorders, blood clots, 
blood pressure conditions, heart failure, hyperlipidaemia, myocardial ischaemia, oedema and vascular 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Table 3: Mean number of daily doses and antibiotic exposure duration by AKI Stage 
 
 
 
 
 
 
 
AKI Stage Stage 1                                                         
        mean (SD) 
Stage 2                                                                
mean (SD) 
Stage 3              
mean(SD) 
Antibiotic Class Number of 
doses per day 
Duration of 
prescription  
(days) 
Number of doses per 
day 
Duration of 
prescription  
(days) 
Number of doses 
per day 
Duration of 
prescription  
(days) 
Cephalosporins 4 (3.14) 6.81 (1.13) 5.04 (4.13) 7.23 (2.17) 6.39 (6.34) 6.38 (0.94) 
Fluoroquinolones 2.32 (2.32) 7.34 (2.98) 2.05 (1.93) 14.64 (10.36) 2.19 (1.63) 8.38 (4.16) 
Macrolides 3.81 (3.55) 7.43 (3.16) 2.84 (2.01) 8.63 (4.99) 4.08 (5.12) 6.92 (1.51) 
Nitrofurantoins 3.61 (5.33) 8.76 (7.22) 3 (1.22) 8.67 (7.38) 3.18 (1.01) 7.5 (1.51) 
Penicillins 4.34 (4.2) 7.21 (2.3) 6.49 (7.84) 7.6 (2.72) 5.09 (5.88) 7.64 (3.65) 
Sulphonamides 
&Trimethoprims 
2.03 (2.3) 8.88 (7.44) 2.7 (5.7) 9.39 (8.12) 2.71 (5.44) 7.76 (5.12) 
Figure 4: Incidence rate ratio (IRR) of AKI for antibiotic subgroup adjusted for age 
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